| Summary: | Taxanes is a new group of antineoplastic agents which is active in several types of cancer. In view of the fact that paclitaxel has a specific prescription, high cost and potentially severe adverse effects, its use was studied in the light of the guidelines established by the American Association of Hospital Pharmacists. The criteria and standards were derived from the literature. A review of the clinical histories of 55 patients treated with paclitaxel between 2000 and 2004 was carried out. The results show a clear trend toward considering including the results of clinical trials in daily practice, which explains deviations in the use of paclitaxel for this prescription (patients had ovarian, breast or lung cancers) and in dosage (only 40% received the current dosages). Paclitaxel was shown to be an effective medication, with a response rate of 48% and moderate toxicity.
|
|---|
Cost-utility and effectiveness in the treatment of prostatic cancer in the social security of province Misiones Argentina